The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar
- Fiorino, Gionata
- Manetti, Natalia
- Armuzzi, Alessandro
- Orlando, Ambrogio
- Variola, Angela
- Bonovas, Stefanos
- Bossa, Fabrizio
- Maconi, Giovanni
- Dʼincà, Renata
- Lionetti, Paolo
- Cantoro, Laura
- Fries, Walter
- Annunziata, Maria L
- Costa, Francesco
- Terpin, Maria M
- Biancone, Livia
- Cortelezzi, Claudio C
- Amato, Arnaldo
- Ardizzone, Sandro
- Danese, Silvio
- Guidi, Luisa
- Rizzuto, Giulia
- Massella, Arianna
- Andriulli, Angelo
- Lorenzon, Greta
- Ghione, Silvia
- Kohn, Anna
- Ventra, Agostino
- Annese, Vito
- the PROSIT BIO Cohort Investigators: Principi M
- Di Girolamo M
- Bertani A
- Saettone S
- Tari R
- Petruzzellis C
- Guglielmi FW
- Mazzuoli S
- Cappello M
- Viola A
- Castiglione F
- Nardone O
- Di Sabatino A
- Saibeni S
- Bezzio C
- Caserta L
- Parodi MC
- Alvisi P
- Meucci G
- Colli A
- Ronchetti A
- Vecchi M
- Bertani L
- Bosani MA
- Tronconi E
- Imperiali G
- Salerno R
- Rogai F
- Milani S
- Pugliese D
- Renna S
- Geccherle A
- Martino G
- Cassinotti A.
- MASSARI, ALESSANDRO
Publication date
January 2017
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease
Add to ORKG